Seattle Genetics, a cancer research, and drug company, has announced its plans to expand its drug portfolio and at the same time employ over 120 people in its US and Switzerland offices. The announcement came amidst recent visit by vice president Joe Bidden who visited the region to see the progress of cancer research.
With the company already having over 800 employees in their books, the larger percentage of the new hires will serve in operations as opposed to research. The US office can hold 350 more people and therefore Seattle Genetics will add 100 new employees in the US while 20 will be employed in the Switzerland office. After hiring about 500 people in the last five years, an average of 100 people annually, there is no doubt the company has been growing rapidly. This year Seattle Genetics is on track to maintain that trend by hiring more than 120 people.
The company puts Seattle on the map and underlines it as a center for cancer research. The master plan by Dr. Seigall includes rolling out 12 new cancer therapy drugs.
According to Dr. Siegall, the results of the drug will largely affect the company. Adcetris, a ‘frontline’ treatment for lymphoma has generated $226 million in revenues in the US and Canada alone. The predicted revenues in 2016 will range between $255 million and $275 million after partnering with a pharmaceutical company that will sell the drug in other parts of the world.
About Clay Siegall
For his education, Dr. Siegall attended the University of Maryland where he earned a B.S degree in Zoology. He is also a Ph.D. holder in Genetics after he achieved his doctorate from Washington University. Dr. Clay Siegall Co-Founded Seattle Genetics Inc. in 1998. He currently serves in three positions within the company. He is the president and CEO as well as the Chairman of the board of directors of the company.
Besides co-establishing Seattle Genetics, Dr. Siegall had experienced a rich history of working in medical having worked for almost a decade for two medical research centers. He is currently a board member of several private biotechnology companies including Ultragenyx Pharmaceuticals, Mirna Therapeutics, and Alder Biopharmaceuticals.